JURA Bio
Company

Last deal

$16.1M

Amount

Seed

Stage

21.09.2023

Date

1

all rounds

$16.1M

Total amount

Financing round

General

About Company
Jura Bio develops cell-based therapies for autoimmune disorders.

Industry

Sector :

Subsector :

Keywords :

Also Known As

JURA

Number of employees

Company Type

For Profit

Last funding type

Seed

IPO status

Private

Description

Founded by Elizabeth Baker Wood and Julie Norville, Jura Bio is a Massachusetts-based therapeutics company that uses gene editing to create allogeneic, off-the-shelf CAR-T cells for the treatment of progressive forms of multiple sclerosis and other autoimmune diseases. The company's therapeutic platform aims to provide patients with curative and definitive cell-based therapies that go beyond disease modification. By leveraging the full potential of gene editing, Jura Bio is translating the successes of CAR-T to autoimmune disorders, offering a promising new approach to treating these challenging conditions.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Abata Therapeutics

Abata Therapeutics

Abata Therapeutics develops cell therapy to treat autoimmune and inflammatory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Cambridge, MA, USA

total rounds

2

total raised

$95M
Skyhawk Therapeutics

Skyhawk Therapeutics

Skyhawk Therapeutics develops small molecule therapeutics to correct RNA expression.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Waltham, MA, USA

total rounds

8

total raised

$181.2M
Sonoma BioTherapeutics

Sonoma BioTherapeutics

Sonoma BioTherapeutics develops adoptive Treg therapies cell for autoimmune.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

South San Francisco, CA, USA

total rounds

5

total raised

$410M
Clade Therapeutics

Clade Therapeutics

Clade Therapeutics is a biopharmaceutical company that develops next-generation stem-cell-based medicines.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Health Care

Location

Cambridge, MA, USA

total rounds

1

total raised

$87M

Financials

Funding Rounds
1
1

Number of Funding Rounds

$16.1M

Money Raised

Their latest funding was raised on 21.09.2023. Their latest investor John Ballantyne. Their latest round Seed

Date 
Funding Round 
Investors 
Money Raised 
Lead 
21.09.2023
6
$16.1M
Co-Investors
Investors
6
0

Number of lead investors

6

Number of investors

Investor 
Lead 
Round 
Partners 

John Ballantyne

count Of Investments

1

Michael Chambers

count Of Investments

1

Josh Ellington

count Of Investments

1

People

Founders
2
Julie Norville
Julie Norville

Julie Norville

Julie Norville is the current Founder , CSO and CTO of JURA Bio. She previously worked at Harvard Medical School as a Research Fellow in Genetics in the Laboratory of George Church. Julie Norville attended Massachusetts Institute of Technology.

current job

JURA Bio
JURA Bio

organization founded

1

Julie Norville

George Church
George Church

George Church

George Church is a leading expert in human genetics and biotechnology.He has served as professor of genetics at Harvard Medical School since 1986 and currently serves as professor of health sciences and technology at Harvard and the Massachusetts Institute of Technology (MIT).He is also director of the U.S. Department of Energy Center on Bioenergy at Harvard and MIT and director of the National Institutes of Health Center of Excellence in Genomic Science at Harvard. Church helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. Church pioneered genome engineering, systems and synthetic biology, and concepts of molecular multiplexing and tags, and he has a successful track record of developing and transferring new technologies to more than 20 companies. Church has received numerous awards, including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute, the 2009 Promega Biotechnology Research Award from the American Society for Microbiology, and was honored in The Scientist’s Top 10 Innovations list in 2008. Church holds a Ph.D. in biochemistry and molecular biology from Harvard University and a B.A. in zoology and chemistry from Duke University.

current job

Colossal Biosciences Boston, Massachusetts
Colossal Biosciences Boston, Massachusetts

organization founded

22

George Church

Employee Profiles
3
Elizabeth Wood

Elizabeth Wood

Founder and CEO

Julie Norville

Julie Norville

Founder , CSO and CTO

George Church

George Church

Co-Founder

Activity

Recent News
0